A study by IIT Delhi has depicted that antibiotic Teicoplanin is more effective than other COVID-19 drugs but further analysis was indicated.
The study had screened an assemblage of 23 approved drugs that had shown lead towards being an option against the infection. Among these, the clinically approved drug Teicoplanin was found to be a potential therapeutic option against COVID-19 that can be 10 to 20 times more effective than currently being used drugs such as Lopinavir and Hydroxychloroquine in the laboratory conditions.
Teicoplanin is an approved glycopeptide antibiotic by the Food and Drug Administration(FDA), which is regularly used for treating Gram-positive bacterial infections with a low toxicity profile in humans.
Previously it was reported that teicoplanin was tested for its efficacy against COVID-19 virus infection, and it was found that teicoplanin potently prevents the entrance of the virus into the cytoplasm.
However, the examination has also pointed out a need for more detailed clinical investigation on a large cohort, in different stages of mild, moderate, and critically ill patients, to conclude the definite role of Teicoplanin against COVID-19.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.